🧠 1. At a Glance
Everest Organics is a small-cap API manufacturer with big dreams and inconsistent execution. It serves molecules from rabeprazole to apixaban — but growth? Bleh. FY25 revenue fell to ₹159 Cr, and ROE is -2.2%. Promoters just dumped 13% stake, and the company’s financials are more volatile than a Twitter IPO. So why is it up 133% in one year? Short answer: speculation, not sales.
🎬 2. Introduction with Hook
Everest Organics sounds like a Himalayan health retreat. But it’s actually a ₹325 Cr micro-cap pharma stock that’s given traders a dopamine hit with its 1-year return — +133%. Is it turning around? Or is this just retail getting high on its own supply?
One glance at the numbers — falling revenue, inconsistent profits, high debtor days (202!), and a mysterious promoter stake cut — and this stock screams “🚨 Proceed with gloves and goggles.”
🧪 3. WTF Do They Even Do? (Business Model)
Everest Organics manufactures:
- APIs: For gastro, antifungal, anti-thrombotic, anti-diabetic, insomnia, and yes — overactive bladder 💦
- Intermediates: For blockbuster drugs like Febuxostat, Apixaban, Itraconazole, Pantoprazole, Oseltamivir, and more
- By-products: Like Ammonium Sulphate and Di-Ammonium Phosphate — sold to fertiliser and chemical companies
They export APIs to regulated and semi-regulated markets. Got USFDA + KDMF approval recently for select molecules.
But while the product basket is fancy, revenue
